GLP-1 Trends
GLP-1 agonists have become increasingly popular as a treatment option for type 2 diabetes and obesity. These medications continue to […]
GLP-1 agonists have become increasingly popular as a treatment option for type 2 diabetes and obesity. These medications continue to […]
In 2024, health systems across the United States navigated a year of significant transformation. Key challenges included heightened scrutiny of
It has been a year of rapid growth for pharmacy benefit managers (PBMs). Take a look at our recap of
PMPM guarantees are now available at Maxor. Small employer groups don’t have a lot of leeway when it comes to
In the United States, 15.8 million people live in pharmacy deserts — areas with limited or no access to a
December marks the start of peak respiratory syncytial virus (RSV) season, which typically lasts through February in most parts of
The 340B program is a major focal point in the pharmaceutical industry, impacting specialty pharmacies, covered entities (CEs), and manufacturers
Biosimilars represent both a significant opportunity and challenge for the biopharmaceutical industry. Download our trend report to learn more about
In the United States, over 38 million people—roughly 1 in 10 Americans—are living with diabetes, a condition that impacts how
Maxor recently conducted a retrospective analysis of claims data to understand the impact of social determinants of health (SDOH) on